MEA Apheresis Market

MEA Apheresis Market Size (2022 to 2027)

As per the research report, the Middle East and Africa Apheresis Market was worth USD 0.16 billion in 2022 and estimated to be growing at a CAGR of 6.86%, to reach USD 0.22 billion by 2027.

The increasing prevalence of chronic diseases, the growing demand for plasma from biopharmaceutical companies, large patient base, trauma and injury cases, more demand for blood diagnosis, and the ever-increasing number of surgeries and favorable reimbursements in the region are primarily accelerating the growth rate of the apheresis market in the Middle East and Africa. According to the 2019 World Federation of Hemophilia report, the number of people identified as having hemophilia increased from 78,630 in 2000 to 324,700 in 2020 worldwide. In addition, approximately 157,520 people worldwide have hemophilia A and around 32,000 people have hemophilia B. All these factors mentioned above are estimated to have a healthy growth for the MEA apheresis market during the forecast period.

Technological advancements in the development of newer apheresis techniques in clinically ill patients are increasing day by day, as primary therapy or as an adjunct to other treatments for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic syndrome, drug toxicity, autoimmune diseases, sepsis, uremia, and hepatic failure. Additionally, according to the report from CDC, it can be estimated that over 45 million adults suffer from chronic kidney disease. Apheresis help in the purification of blood for patients suffering from kidney disorders. In a recent study, the prevalence of renal diseases seen among UAE residents was over 4.5% in males and 2.9% in females. While in the Kingdom of Saudi Arabia, the prevalence of chronic kidney disorder in the Saudi population was recorded at around 5.8%. Along with these factors, the increasing number of product approvals and innovations has driven the growth of the MEA apheresis market.

However, the inherent high cost of apheresis therapy is expected to hamper the growth of the MEA apheresis market during the forecast period. In addition, the risks associated with apheresis such as complications related to fluid transfer, side effects related to the use of fresh frozen plasma (FFP), risk of hepatitis or allergic reactions, or hypoglycemia due to the use of large amounts of citrate, all these factors are also expected to limit the growth of the market in the years to come. Furthermore, the shortage of blood donors and skilled technicians in some rural MEA regions also holds back the market's growth.

This research report on the Middle East and Africa Apheresis Market has been segmented and sub-segmented into the following categories:

By Product: 

• Devices
• Disposables

By Procedure: 

• Donor
• Therapeutic
• Photopheresis

By Application: 

• Renal Diseases
• Neurology
• Cancer
• Hematology
• Autoimmune Diseases
• Cardiovascular Diseases

By Technology: 

• Centrifuge
• Membrane Separation

By End User: 

• Private Blood Collection Centres
• Public Blood Collection Centres
• Hospitals

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The private sector plays a key role in bankrolling the healthcare sector in Africa, with more than 50% of their investment. The apheresis market is growing slowly because of many problems the region faces, battles, and the unstable economy. However, countries like the USA, China, and the UK are investing in the region, and this increased financial revenue will aid the healthcare sectors in this region. This region has a global share of 8% and has a CAGR of 6.86%.

In 2020, the Kingdom of Saudi Arabia dominated the MEA market for apheresis and will continue to be a significant share during the analysis period. The sustained increase in demand for blood components, high incidence of chronic diseases such as cardiovascular disease, leukemia, and sickle cell anemia, large population, are increasing the demand for apheresis in the region. In addition, the constant shortage of blood and the need to ensure the safety of the blood supply also prompts a focus on blood by apheresis.

The regional market in African countries is expected to see growth attributed to the growing awareness regarding the advantages of apheresis over whole blood collection and the increasing demand for plasma from biopharmaceutical companies. In addition, the promising outlook for the African region is mainly due to the rising prevalence of blood-related disorders in developing economies.

Meanwhile, the United Arab Emirates remains the market showing the highest growth rate in the MEA apheresis market due to factors such as increased patient spending, reimbursement policies, and growing patient awareness. Government support, availability of skilled professionals, and the demand for advanced blood collection technologies support market growth in this region. In addition, the market has seen growth in the past several years thanks to greater willingness to donate blood and safety precautions during the procedure.

KEY MARKET PLAYERS:

Companies playing a prominent role in the MEA apheresis market profiled in the report are Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, Terumo BCT, Inc., Fresenius Medical Care, Kawasumi Laboratories Inc., Cerus Corporation, HemaCare Corporation, Kaneka Corporation, B. Braun Melsungen AG, and Nikkiso Co., Ltd., Therakos, Inc., and Medica S.p.A.